+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Doxorubicin Market by Indication (Breast Cancer, Kaposi Sarcoma, Leukemia), Formulation (Liposomal Injection, Lyophilized Powder), Distribution Channel, End User, Administration Route, Patient Age Group - Global Forecast 2025-2030- Product Image
Doxorubicin Market by Indication (Breast Cancer, Kaposi Sarcoma, Leukemia), Formulation (Liposomal Injection, Lyophilized Powder), Distribution Channel, End User, Administration Route, Patient Age Group - Global Forecast 2025-2030- Product Image
Sale

Doxorubicin Market by Indication (Breast Cancer, Kaposi Sarcoma, Leukemia), Formulation (Liposomal Injection, Lyophilized Powder), Distribution Channel, End User, Administration Route, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082554
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Doxorubicin continues to play a central role in the evolving oncology landscape, serving as a benchmark for therapeutic effectiveness, adaptability, and cost efficiency in cancer care. Market participants must navigate a complex interplay of drug innovation, regulatory shifts, and supply chain management to secure a strong position in the global doxorubicin market.

Market Snapshot: Doxorubicin Market Overview

The doxorubicin market grew from USD 2.65 billion in 2024 to USD 2.95 billion in 2025. It is expected to continue growing at a CAGR of 10.85%, reaching USD 4.92 billion by 2030. This growth trajectory reflects the broad clinical adoption of doxorubicin across multiple oncology indications, including its integration into both new and existing treatment protocols. The market remains highly responsive to both technological and regulatory developments that affect global and regional dynamics.

Scope & Segmentation

This research provides a comprehensive analysis of the doxorubicin market, detailing its scope across therapeutic, product, and delivery innovations as well as regional and end-user considerations. The segmentation covers:

  • Indications: Breast cancer (spanning first, second, and third-line therapy), Kaposi sarcoma, leukemia, and ovarian cancer.
  • Formulation Types: Liposomal injections (including both non-pegylated and pegylated) and lyophilized powder formats.
  • Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy channels supporting diverse patient pathways.
  • End Users: Ambulatory surgical centers, cancer treatment centers, home care settings, and hospitals.
  • Administration Routes: Central and peripheral venous catheter infusions, tailored for varied dosing regimens.
  • Patient Age Groups: Solutions optimized for adult and pediatric populations, reflecting differences in treatment protocols and toxicity management.
  • Geographies Covered: Detailed insights across the Americas (including the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (with focus countries such as the United Kingdom, Germany, France, Russia, Saudi Arabia, South Africa, and more), and Asia-Pacific (covering China, India, Japan, Australia, among others).
  • Company Analysis: In-depth review of competitive strategies and capabilities for Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Baxter International Inc., Dr. Reddy's Laboratories Limited, Cipla Limited, Apotex Inc., and Hikma Pharmaceuticals PLC.

Doxorubicin Market Key Takeaways

  • Continued innovation in drug delivery—particularly the move towards liposomal and pegylated formulations—enables clinicians to target tumors while minimizing systemic toxicity and side effects.
  • Strategically diversified sourcing and nearshoring initiatives strengthen supply chain resilience in response to global tariff and trade challenges.
  • Partnerships between major manufacturers, regional producers, and academic research centers are accelerating clinical development and expanding access in emerging markets.
  • Digital health platforms are gaining traction for remote patient monitoring, directly supporting adherence, personalized dosing, and real-world evidence generation.
  • Value-based contracting and risk-sharing agreements are increasingly central to payer negotiations, supporting the adoption of advanced formulations in regulated markets.

Tariff Impact: Regulatory and Supply Chain Considerations

Recent United States tariff policies enacted in 2025 have significantly altered the cost structure for doxorubicin manufacturing, especially in sourcing key intermediates. Manufacturers are reacting by pursuing diversified supply channels, forging relationships in favorable regions, and adjusting logistics strategies to sustain production continuity and market access. Hospital pharmacies and clinics are adapting procurement and contracting practices to address input cost volatility and maintain reliable patient care delivery.

Methodology & Data Sources

This analysis integrates rigorous secondary research from peer-reviewed literature, regulatory filings, and industry reports, with primary validation from structured interviews with key stakeholders across oncology, supply chain, and patient advocacy organizations. The data governance framework includes consistency audits and cross-verification to ensure accuracy and thematic relevance.

Why This Report Matters

  • Enables executives to navigate regulatory complexities and global supply risks with actionable intelligence for strategic decision-making.
  • Provides a multidimensional view of market drivers—clinical, technological, and regional—to support portfolio optimization and resource allocation.
  • Assists in identifying opportunities for collaboration, differentiation, and competitive advantage within the evolving oncology therapeutic landscape.

Conclusion

The doxorubicin market is distinguished by continuous innovation, proactive response to regulatory and supply challenges, and dynamic stakeholder collaboration. Strategic decisions grounded in robust market intelligence will shape future advancements and competitive positioning in oncology therapeutics.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Adoption of liposomal and nanocarrier formulations to improve tumor targeting and reduce cardiotoxicity of doxorubicin
5.2. Evaluation of combination regimens pairing doxorubicin with immune checkpoint inhibitors in solid tumor therapy
5.3. Expansion of generic doxorubicin market in emerging economies driven by biosimilar approvals
5.4. Implementation of real-time cardiac monitoring protocols to mitigate doxorubicin-induced cardiomyopathy risk
5.5. Research into mitoprotective adjuvants to attenuate oxidative damage in patients receiving doxorubicin chemotherapy
5.6. Advances in personalized dosing algorithms using pharmacogenomic profiling for doxorubicin administration
5.7. Regulatory updates on maximum lifetime dose restrictions for doxorubicin and their market implications
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Doxorubicin Market, by Indication
8.1. Introduction
8.2. Breast Cancer
8.2.1. First Line
8.2.2. Second Line
8.2.3. Third Line
8.3. Kaposi Sarcoma
8.4. Leukemia
8.5. Ovarian Cancer
9. Doxorubicin Market, by Formulation
9.1. Introduction
9.2. Liposomal Injection
9.2.1. Non Pegylated Liposomal
9.2.2. Pegylated Liposomal
9.3. Lyophilized Powder
10. Doxorubicin Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Doxorubicin Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Cancer Treatment Centers
11.4. Home Care Settings
11.5. Hospitals
12. Doxorubicin Market, by Administration Route
12.1. Introduction
12.2. Central Venous Catheter
12.3. Peripheral Venous Catheter
13. Doxorubicin Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Pediatric
14. Americas Doxorubicin Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Doxorubicin Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Doxorubicin Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. Teva Pharmaceutical Industries Ltd.
17.3.3. Novartis AG
17.3.4. Sun Pharmaceutical Industries Ltd.
17.3.5. Fresenius Kabi AG
17.3.6. Baxter International Inc.
17.3.7. Dr. Reddy's Laboratories Limited
17.3.8. Cipla Limited
17.3.9. Apotex Inc.
17.3.10. Hikma Pharmaceuticals PLC
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. DOXORUBICIN MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DOXORUBICIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DOXORUBICIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DOXORUBICIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DOXORUBICIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DOXORUBICIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DOXORUBICIN MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DOXORUBICIN MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DOXORUBICIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DOXORUBICIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DOXORUBICIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DOXORUBICIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DOXORUBICIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DOXORUBICIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DOXORUBICIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DOXORUBICIN MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. DOXORUBICIN MARKET: RESEARCHAI
FIGURE 28. DOXORUBICIN MARKET: RESEARCHSTATISTICS
FIGURE 29. DOXORUBICIN MARKET: RESEARCHCONTACTS
FIGURE 30. DOXORUBICIN MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DOXORUBICIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DOXORUBICIN MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DOXORUBICIN MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DOXORUBICIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DOXORUBICIN MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DOXORUBICIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DOXORUBICIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DOXORUBICIN MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DOXORUBICIN MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DOXORUBICIN MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DOXORUBICIN MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DOXORUBICIN MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DOXORUBICIN MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DOXORUBICIN MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DOXORUBICIN MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DOXORUBICIN MARKET SIZE, BY KAPOSI SARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DOXORUBICIN MARKET SIZE, BY KAPOSI SARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DOXORUBICIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DOXORUBICIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DOXORUBICIN MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DOXORUBICIN MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DOXORUBICIN MARKET SIZE, BY NON PEGYLATED LIPOSOMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DOXORUBICIN MARKET SIZE, BY NON PEGYLATED LIPOSOMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DOXORUBICIN MARKET SIZE, BY PEGYLATED LIPOSOMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DOXORUBICIN MARKET SIZE, BY PEGYLATED LIPOSOMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DOXORUBICIN MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DOXORUBICIN MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DOXORUBICIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DOXORUBICIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DOXORUBICIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DOXORUBICIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DOXORUBICIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DOXORUBICIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DOXORUBICIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DOXORUBICIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DOXORUBICIN MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DOXORUBICIN MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL DOXORUBICIN MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL DOXORUBICIN MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL DOXORUBICIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL DOXORUBICIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL DOXORUBICIN MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL DOXORUBICIN MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL DOXORUBICIN MARKET SIZE, BY PERIPHERAL VENOUS CATHETER, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL DOXORUBICIN MARKET SIZE, BY PERIPHERAL VENOUS CATHETER, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL DOXORUBICIN MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL DOXORUBICIN MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL DOXORUBICIN MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL DOXORUBICIN MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS DOXORUBICIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS DOXORUBICIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES DOXORUBICIN MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES DOXORUBICIN MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 105. CANADA DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. CANADA DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. CANADA DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 108. CANADA DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 109. CANADA DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 111. CANADA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 112. CANADA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 113. CANADA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. CANADA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. CANADA DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. CANADA DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. CANADA DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 118. CANADA DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 119. CANADA DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 120. CANADA DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 121. MEXICO DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 124. MEXICO DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 125. MEXICO DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 126. MEXICO DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 127. MEXICO DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 128. MEXICO DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 129. MEXICO DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. MEXICO DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. MEXICO DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. MEXICO DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. MEXICO DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 134. MEXICO DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 135. MEXICO DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 136. MEXICO DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 203. GERMANY DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 204. GERMANY DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 205. GERMANY DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 206. GERMANY DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 207. GERMANY DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 208. GERMANY DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 209. GERMANY DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 210. GERMANY DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 211. GERMANY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. GERMANY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. GERMANY DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. GERMANY DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. GERMANY DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 216. GERMANY DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 217. GERMANY DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 218. GERMANY DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 219. FRANCE DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. FRANCE DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. FRANCE DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 222. FRANCE DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 223. FRANCE DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 224. FRANCE DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 225. FRANCE DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 226. FRANCE DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 227. FRANCE DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. FRANCE DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. FRANCE DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. FRANCE DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. FRANCE DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 232. FRANCE DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 233. FRANCE DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 234. FRANCE DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 251. ITALY DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. ITALY DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. ITALY DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 254. ITALY DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 255. ITALY DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 256. ITALY DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 257. ITALY DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 258. ITALY DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 259. ITALY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. ITALY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. ITALY DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. ITALY DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. ITALY DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 264. ITALY DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 265. ITALY DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 266. ITALY DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 267. SPAIN DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. SPAIN DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. SPAIN DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 270. SPAIN DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 271. SPAIN DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 272. SPAIN DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 273. SPAIN DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 274. SPAIN DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 275. SPAIN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. SPAIN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. SPAIN DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. SPAIN DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. SPAIN DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 280. SPAIN DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 281. SPAIN DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 282. SPAIN DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 314. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 320. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 322. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 324. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 328. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 329. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 330. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 331. DENMARK DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 332. DENMARK DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 333. DENMARK DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 334. DENMARK DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 335. DENMARK DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 336. DENMARK DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 337. DENMARK DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 338. DENMARK DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 339. DENMARK DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 340. DENMARK DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 341. DENMARK DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 342. DENMARK DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 343. DENMARK DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 344. DENMARK DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 345. DENMARK DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 346. DENMARK DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 347. NETHERLANDS DOXORUBICIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 348. NETHERLANDS DOXORUBICIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 349. NETHERLANDS DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 350. NETHERLANDS DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 351. NETHERLANDS DOXORUBICIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 352. NETHERLANDS DOXORUBICIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 353. NETHERLANDS DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2018-2024 (USD MILLION)
TABLE 354. NETHERLANDS DOXORUBICIN MARKET SIZE, BY LIPOSOMAL INJECTION, 2025-2030 (USD MILLION)
TABLE 355. NETHERLANDS DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 356. NETHERLANDS DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 357. NETHERLANDS DOXORUBICIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 358. NETHERLANDS DOXORUBICIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 359. NETHERLANDS DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 360. NETHERLANDS DOXORUBICIN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 361. NETHERLANDS DOXORUBICIN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD

Samples

Loading
LOADING...

Companies Mentioned

  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG
  • Baxter International Inc.
  • Dr. Reddy's Laboratories Limited
  • Cipla Limited
  • Apotex Inc.
  • Hikma Pharmaceuticals PLC

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.95 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.92 Billion
Compound Annual Growth Rate10.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Liposomal Doxorubicin Market Report and Forecast 2025-2034 - Product Image

Liposomal Doxorubicin Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Doxorubicin Hydrochloride API Market by Application (Breast Cancer, Leukemia, Lymphoma), End User (Contract Research Organizations, Hospitals, Pharmaceutical Companies), Grade, Form, Distribution Channel - Global Forecast 2025-2030 - Product Image

Doxorubicin Hydrochloride API Market by Application (Breast Cancer, Leukemia, Lymphoma), End User (Contract Research Organizations, Hospitals, Pharmaceutical Companies), Grade, Form, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Liposomal Doxorubicin Market Report 2025 - Product Image

Liposomal Doxorubicin Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Doxorubicin Market Report 2025 - Product Image

Doxorubicin Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 80 Pages
  • Global
From

About the Doxorubicin Market

Doxorubicin is an oncology drug used to treat a variety of cancers, including leukemia, lymphoma, and breast, ovarian, and bladder cancer. It is a type of anthracycline antibiotic, derived from Streptomyces peucetius, and works by interfering with the growth of cancer cells. It is administered intravenously, and is often used in combination with other drugs. Doxorubicin is one of the most widely used chemotherapy drugs, and is often used in combination with other drugs to treat a variety of cancers. It is also used to treat Kaposi's sarcoma, a type of skin cancer. Side effects of doxorubicin include nausea, vomiting, hair loss, and an increased risk of infection. The doxorubicin market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.